ABSTRACT Increased production of the serum protease plasminogen activator is associated with tissue damage. The in vitro production of plasminogen activator by alveolar macrophages obtained by bronchoalveolar lavage was studied in 22 normal subjects and 28 patients with interstitial lung disease to determine whether plasminogen activator is produced by normal alveolar macrophages and whether this is increased in patients with interstitial lung disease. Plasminogen activator activity, measured with an iodine-125 labelled fibrin release assay, was found to be dependent on time, effector cell numbers, and plasminogen concentration. Plasminogen activator production by alveolar macrophages from 14 normal non-smokers and eight normal smokers was similar and the mean value was 0-78 (SEM 0 16) urokinase (UK) units x 10-8/cell/hour. Alveolar macrophages from the seven patients with cryptogenic fibrosing alveolitis and six patients with histiocytosis-X produced more plasminogen activator (1 89 (0-25) and 4 54 (1 3) x 10-8 UK units/cell/hour respectively) than macrophages from normal subjects (p < 005), whereas those from 15 patients with sarcoidosis did not (1 09 (02) x 10-' UK units/cell/hour). Exposure of normal alveolar macrophages to immune complexes enhanced plasminogen activator production to 2-07 (0 27) x 10-' UK units/cell/hour, whereas exposure to products of activated T cells and to purified y interferon reduced plasminogen activator production (to 0-38 (0 11) and 0-62 (0-11) x 10' UK units/cell/hour respectively). These studies show that plasminogen activator is produced by normal human alveolar macrophages and that its production is increased in patients with cryptogenic fibrosing alveolitis and histiocytosis-X.
Introduction
Plasminogen activator is a serine protease that converts plasminogen to the active enzyme plasmin, thus participating in the initiation and enhancement of several important biological processes, including fibrin.olysis, inflammation, and connective tissue degradation. ' The role of plasminogen activator in inflammation is related to its capacity to activate complement components' and also to activate Hageman factor to generate bradykinin.7 During inflammatory processes plasminogen activator is released by several cell types, particularly mononuclear phagocytes, and the amount of plasminogen activator produced corresponds to the intensity of inflammation. 8 The role of plasminogen activator in the degradation of connective tissue Production ofplasminogen activator by alveolar macrophages Methods STUDY POPULATION We studied 22 normal volunteers, 14 non-smokers and eight smokers (all with normal chest radiographs and normal pulmonary function and not receiving any treatment), and 28 patients with chronic interstitial lung disease (seven with cryptogenic fibrosing alveolitis, six with pulmonary histiocytosis-X, and 15 with pulmonary sarcoidosis). The diagnosis was confirmed by histological examination of lung biopsy material-open biopsy for patients with cryptogenic fibrosing alveolitis and histiocytosis-X, transbronchial biopsy for those with sarcoidosis-on the basis of established criteria.2' 22 The protocol received the ethical committee's approval and informed consent was obtained from all subjects before the study. PREPARATION To confirm that the activity observed was due to plasminogen activator and not to other fibrin degrading proteases such as elastase, we performed two additional experiments. Firstly, macrophages were studied in the absence of plasminogen and, secondly, a specific inhibitor of plasminogen activator, ac-gly-glyarg chloromethyl ketone (supplied by R Goldfarb, Pfizer, Groton, Connecticut), was added to wells containing alveolar macrophages plus plasminogen.
Maximum inhibition occurred at 100 pg/ml and was used in all experiments. This inhibitor had no effect on background release of '251 (p > 0 3). Each fibrinogen coated plate prepared from the same 1251 fibrinogen batch had similar levels of 1251 release for a given dose of urokinase over periods of up to two months. Slight differences in the 1251I fibrinogen coated plates occur with each new batch, because of variability in 1251 labelling, "cold" fibrinogen concentrations, and the respective proportions of these components in each batch. Alveolar macrophages from at least three normal individuals were therefore studied with each of the three batches. Mean (SEM)% cpm released by these normal macrophages from each of the three plate batches were 31 3 (4 1), 26 3 (4-4), and 50 7 (4 6). To validate comparisons with macrophages from individuals with interstitial lung disease, we related all data to the initial plate batch, using this formula: urokinase activity = (% released by test macrophages -mean % released by normal macrophages with that batch) x 31 3. Assays were performed in triplicate.
EFFECT OF MACROPHAGE STIMULI ON PLASMINOGEN ACTIVATOR PRODUCTION
The capacity of immune complexes and lymphokines to stimulate normal alveolar macrophages to produce increased plasminogen activator activity was determined as follows. Ox red blood cell (ORBC)-anti-ORBC antibody complexes were formed.25 A T cell lymphokine preparation was prepared by incubating normal peripheral blood mononuclear cells in medium containing 10% fetal calf serum plus 20 The effect of these preparations on plasminogen activator production by normal alveolar macrophages was determined as follows. The ORBC-anti-ORBC antibody immune complexes (1% by volume), lymphokine preparation (20% by volume), purified y interferon (200 units/ml), or medium alone was added to wells containing 2-5 x 105 normal alveolar macrophages, and plasminogen activator activity was measured as described above. None of the stimuli altered macrophage adherence, background counts, or release of '25I by purified urokinase plus plasminogen (p > 0 3, all comparisons); this confirmed that the observed alterations in plasminogen activator production were due to a direct effect on macrophages rather than to effects on the plasminogen activator assay. hours, after which the rate of "25I fibrin breakdown declined (fig 2a) . Sonicated alveolar macrophages produced less than 20% of the plasminogen activator activity of an equal number of cultured alveolar macrophages, suggesting that plasminogen activator was largely synthesised de novo during the culture period. The addition of a fresh source of plasminogen activator activity (fresh alveolar macrophages or urokinase) to these wells after 24 hours produced further 1251 fibrin breakdown (data not shown), implying that this decline in plasminogen activator production with time was largely due to decreased production by effector cells rather than to substrate depletion. The degradation of 1251 fibrin by normal alveolar macrophages was linear with respect to cell number up to 5 x 1O0 macrophages/well (fig 2b) . When more macrophages were added to each well the rate of 125I release declined.
Plasminogen activator was partially released into the supernatant and not totally membrane bound as appreciable plasminogen activator activity was detected in the supernatant after four hours of culture in suspension (9 8% (1[3%) of the plasminogen activator activity of an equivalent number of adherent cells) and maximal '25I release was observed with submaximal cell numbers in each well in the presence of ample substrate (fig 2a) .
No significant difference was noted in plasminogen activator production by alveolar macrophages activator activity in mononuclear cell populations from sarcoid lungs was associated with alveolar macrophages as purified lung lymphocytes from these patients showed negligible plasminogen activator activity ( < 109 units per cell/h). The fibrinolytic activity of the alveolar macrophages from each group of patients like those from normal subjects, was shown to be due to plasminogen activator since it was plasminogen dependent and inhibited by the specific plasminogen activator inhibitor ac-gly-gly-arg chloromethyl ketone (p < 0-001 for both cryptogenic fibrosing alveolitis and histiocytosis-X compared with macrophages plus plasminogen without inhibitor). The effects of these stimuli were manifest within two hours of being applied to alveolar macrophage cultures.
Discussion
Plasminogen activator has a variety of physiological and pathological activities, depending on the cell origin, the location of its production, and the presence or absence of factors that regulate its production.
PRODUCTION OF PLASMINOGEN ACTIVATOR BY NORMAL ALVEOLAR MACROPHAGES
The immediate and sustained plasminogen activator production contrasts with the production of neutrophil chemotactic factor under similar conditions,25 and with murine plasminogen activator production,'4 Production ofplasminogen activator by alveolar macrophages implying that normal human alveolar macrophages are "primed" to produce plasminogen activator in vivo. This suggests that the production ofplasminogen activator has a role in vivo in the normal human lung, a suggestion that is supported by the observation that plasminogen activator activity is present in extracted normal lung tissue27 and in the epithelial lining fluid of the normal lower respiratory tract (paper in preparation). The role of plasminogen activator in the normal lung may be similar to its role in other normal tissues-that is, tissue remodelling and prevention of clot formation2 by clearance of fibrinogen.28 Although appreciable amounts were released, the activity of plasminogen activator in normal alveolar macrophages was largely bound to the cell membrane, as noted in human blood monocytes.9 Membrane bound plasminogen activator is largely protected from inhibition by antiproteases30 and is thus able to act freely on the substrates with which the macrophage makes contact.
EFFECTS OF SMOKING ON PLASMINOGEN ACTIVATOR PRODUCTION
Although cigarette smoking induces human alveolar macrophages to produce increased amounts of some mediators-for example, oxygen radicals3"-this study shows no such effect on plasminogen activator production. Although total plasminogen activator activity in the lower respiratory tract of smokers is likely to be increased because of their increased number of alveolar macrophages,32 whether plasminogen activator has a role in the destruction of alveolar structures from cigarette smoking remains uncertain.
PLASMINOGEN ACTIVATOR RELEASE IN INTERSTITIAL LUNG DISEASES
Plasminogen activator release was increased in most patients with cryptogenic fibrosing alveolitis and histiocytosis-X. Loss of type I epithelial cells and basement membrane damage are seen in cryptogenic fibrosing alveolitis33 and histiocytosis-X.' In view of the capacity of plasminogen activator to degrade laminin and fibronectin, important structural and cell attachment components ofbasement membrane,'0 and to activate latent collagenases,'2 possibly increased plasminogen activator activity in these diseases induces damage to basement membrane, which may then prevent type II epithelial cells from reconstituting the epithelial surface, thus leading to repair by fibrosis.3 Plasminogen activator also directly degrades other lung connective tissue proteins35 and this may also contribute to the tissue damage in these disorders.
Further support for a role for plasminogen activator in the inflammation and tissue destruction in patients with interstitial lung disease comes from several animal disease models. Plasminogen activator correlates closely with the degree of inflammation and damage in cutaneous leprosy in mice,'7 chronic subcutaneous inflammation in sheep,'8 and chronic hypersensitivity pneumonitis in rabbits.'3 In addition, increased plasminogen activator production corresponds to the degree of inflammation and tissue damage in patients with chronic inflammatory bowel disease,'9 rheumatoid arthritis,20 and psoriasis.36
Interestingly, sarcoidosis, a disease that is generally less aggressive and destructive,2' is not associated with the production of abnormal amounts of plasminogen activator by alveolar macrophages. As the alveolar macrophages in sarcoidosis are activated,26 clearly the nature of this activation differs from that seen in cryptogenic fibrosing alveolitis and histiocytosis-X, suggesting either that a different population of cells is present or that the activation signals in the different diseases induce different "types" of alveolar macrophage activation.
EFFECTS OF EXTERNAL STIMULI ON PLASMINOGEN ACTIVATOR PRODUCTION
The aetiology of cryptogenic fibrosing alveolitis is unknown but immune complexes might play a part by activating macrophages.2' In this study immune complexes induced in vitro changes in normal alveolar macrophage plasminogen activator production that mimic the changes seen in alveolar macrophages in patients with cryptogenic fibrosing alveolitis in vivo. Animal studies using alveolar macrophages have also shown that immune complexes enhance plasminogen activator production.5 Interestingly, the addition of immune complexes to alveolar macrophages from patients with cryptogenic fibrosing alveolitis did not further increase plasminogen activator production (data not shown). The aetiology of histiocytosis-X is unknown, but immune complexes have been found in this disease also and may have a role in pathogenesis. Possibly, however, the abnormal cell type that accumulates in the lung in this disorder, the "histiocytosis-X cell," which has some similarities to the antigen presenting dendritic cell,"7 is able to produce large amounts of plasminogen activator.
The aetiology of pulmonary sarcoidosis is also unknown but the disease is associated with the accumulation of large numbers of activated T cells that release large amounts of the macrophage activating factor y interferon. 26 The finding in this study that products of activated T cells, particularly y interferon (though not necessarily exclusively), reduce plasminogen activator production is consistent with the observation that its production by alveolar macrophages from patients with sarcoidosis is not increased, even though these macrophages, like those in cryptogenic fibrosing alveolitis and histiocytosis-X, are activated.26 This effect of activated T cell products and 514 purified y interferon on plasminogen activator production contrasts with that noted with animal peritoneal'4 and alveolar macrophages'3 and with human peripheral blood monocytes,29 where activated T cell products enhance plasminogen activator production. This reduction in fibrinolysis induced by y interferon may be due to reduced plasminogen activator release, "internalisation" of membrane bound plasminogen activator, negative feedback on the producer cell, cell cytotoxicity, or the release of a plasminogen activator inhibitor. None of these possibilities is directly addressed in this study.
This differential production of plasminogen activator in response to different activation stimuli shows that its production is not useful as a "general" marker for macrophage activation, as has been suggested for animal macrophages.38 It also implies a heterogeneity of response of normal human alveolar macrophages to different stimuli. These observations confirm the complexity of human alveolar macrophage responses to different stimuli and implies that study of the production of mediators such as plasminogen activator by alveolar macrophages in different diseases may provide clues about the initiating events in these disorders.
This study shows that normal human alveolar macrophages produce plasminogen activator and that increased amounts of this are released by alveolar macrophages in patients with destructive interstitial lung diseases such as cryptogenic fibrosing alveolitis and histiocytosis-X. Possibly suppressing the release or the effects of plasminogen activator in the lung may be useful in patients with cryptogenic fibrosing alveolitis and histiocytosis-X.
